Price proves NICE sticking point for Celgene's Vidaza
This article was originally published in Scrip
Executive Summary
After being told to reappraise Celgene's anticancer Vidaza (5-azacitidine) for treating myelodysplastic syndromes (MDS), NICE, the health technology institute for England and Wales, still says that the drug is too expensive for use on the NHS, despite acknowledging it to be clinically effective.